Skip to main content
Altimmune, Inc. logo

Altimmune, Inc. — Investor Relations & Filings

Ticker · ALT ISIN · US02155H1014 LEI · 549300EOYCQ8SW3NVE64 US Manufacturing
Filings indexed 1,027 across all filing types
Latest filing 2026-05-13 Registration Form
Country US United States of America
Listing US ALT

About Altimmune, Inc.

https://altimmune.com/

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics. The company's primary areas of development are treatments for obesity and liver diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate is pemvidutide. Altimmune also develops immune-modulating therapies for a range of diseases.

Recent filings

Filing Released Lang Actions
S-8 - Altimmune, Inc. (0001326190) (Filer)
Registration Form
2026-05-13 English
8-K - Altimmune, Inc. (0001326190) (Filer)
Regulatory Filings
2026-05-13 English
424B5 - Altimmune, Inc. (0001326190) (Filer)
Prospectus
2026-04-22 English
8-K - Altimmune, Inc. (0001326190) (Filer)
Regulatory Filings
2026-04-16 English
SCHEDULE 13G/A - Altimmune, Inc. (0001326190) (Subject)
Major Shareholding Notification
2026-03-26 English
ARS - Altimmune, Inc. (0001326190) (Filer)
Annual Report
2026-03-17 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.